Many overweight adults with knee pain, back pain, sciatica, hip pain, or painful walking are now asking a practical question:

“Should I consider a GLP-1 pathway or a dual GIP / GLP-1 pathway?”

This is especially relevant when conventional exercise advice keeps failing because movement hurts.

The important answer is:

These are prescription medical pathways, not casual slimming tools. Suitability depends on proper physician assessment, medical history, risks, tolerability, and treatment goals.

For pain-limited patients, the decision is not only about appetite and weight.

It is also about preserving:

• strength
• mobility
• walking tolerance
• function
• rehabilitation capacity

---

“For pain-limited patients, weight management should not be separated from movement capacity. Losing weight matters, but preserving function matters too.”
— Singapore musculoskeletal physician Dr Terence Tan

---

What Is A GLP-1 Receptor Agonist Pathway?

GLP-1 stands for glucagon-like peptide-1.

GLP-1 receptor agonist pathways act on hormone signalling involved in:

• appetite regulation
• satiety
• gastric emptying
• glucose metabolism

In obesity care, GLP-1 therapies are now recognized internationally as part of medical obesity management for selected adults, but guidelines emphasize appropriate medical assessment, behavioural support, long-term safety considerations, cost, and health-system limitations. (World Health Organization)

Clinical trial evidence has shown meaningful average weight reduction with GLP-1 receptor agonist therapy when combined with lifestyle intervention in adults with overweight or obesity. In one major trial, participants using a once-weekly GLP-1 pathway had substantially greater mean weight reduction than placebo over 68 weeks. (PubMed)

---

What Is A Dual GIP / GLP-1 Pathway?

GIP stands for glucose-dependent insulinotropic polypeptide.

A dual GIP / GLP-1 pathway acts on both:

• GIP receptor signalling
• GLP-1 receptor signalling

These are sometimes described as dual incretin pathways.

The concept is that two incretin-related pathways may influence appetite, glucose handling, metabolic regulation, and weight reduction in selected patients.

In a major obesity trial, adults receiving a dual GIP / GLP-1 pathway had average weight reductions of about 19.5% to 20.9% at higher studied doses over 72 weeks. (New England Journal of Medicine)

---

Is Dual GIP / GLP-1 “Better” Than GLP-1?

Not automatically.

From a broad educational perspective, dual incretin pathways may produce larger average weight reductions in some clinical trial settings, but individual suitability depends on:

• medical history
• BMI and risk profile
• diabetes status
• medication tolerance
• contraindications
• cost
• patient preference
• long-term adherence
• monitoring needs

A larger average trial result does not mean it is the right option for every person.

For real patients, the question is not:

“Which medication class is strongest?”

The better question is:

“Which medically supervised pathway fits my health profile, pain limitations, function goals, and long-term plan?”

---

Why This Matters For Patients With Joint Pain Or Back Pain

Many weight loss clinics focus mainly on:

• appetite
• calories
• medication access
• body weight

But pain-limited patients often have a different problem.

They may be unable to sustain:

• walking
• gym training
• stairs
• jogging
• long standing
• daily movement volume

because of:

• knee osteoarthritis
• back pain
• sciatica
• spinal stenosis
• plantar fasciitis
• Achilles pain
• hip pain
• deconditioning

For these patients, medication alone may reduce weight, but it does not automatically restore movement quality.

---

Medication Alone May Not Rebuild Function

A person may lose weight and still struggle with:

• weak quadriceps
• poor walking tolerance
• fear of movement
• painful stairs
• poor balance
• low endurance
• recurrent back flare-ups
• altered gait mechanics

This is why musculoskeletal planning matters.

For selected patients, an integrated pathway may include:

• physician assessment
• medical weight management
• pain diagnosis
• rehabilitation planning
• progressive strengthening
• safe activity progression
• function preservation

This is the key difference between a generic weight loss pathway and a pain-limited musculoskeletal weight management pathway.

---

What About Lean Mass And Muscle Loss?

This must be discussed clearly.

Meaningful weight reduction can involve reductions in both:

• fat mass
• lean mass

This is not unique to one medication class.

It may occur with:

• calorie restriction
• rapid weight loss
• bariatric pathways
• prescription anti-obesity pharmacotherapy
• reduced physical activity

In a major GLP-1 obesity trial, body composition sub-analysis suggested greater reduction in fat mass than lean mass, but lean mass changes still remain clinically relevant when planning treatment. (New England Journal of Medicine)

For pain-limited adults, this issue matters more because they may already be moving less.

If pain prevents strengthening or walking, then preserving:

• leg strength
• trunk support
• walking ability
• balance
• endurance
• independence

becomes strategically important.

---

Why Physiotherapy Support Is A Major Differentiator

AHPC-registered physiotherapy support may help pain-limited patients with:

• gait assessment
• movement retraining
• progressive strengthening
• walking tolerance rebuilding
• stair retraining
• lower limb loading progression
• neuromuscular control
• safe activity planning

The goal is not simply to “exercise more.”

The goal is to rebuild capacity in a way that matches the patient’s pain condition.

---

When Diagnostic Clarity Matters

Not everyone needs imaging.

But where clinically appropriate, diagnostic clarity may help answer questions such as:

• Why does walking hurt?
• Is this knee pain, hip pain, spine-related pain, or tendon pain?
• Is exercise worsening the wrong structure?
• Is there nerve irritation?
• Is there severe joint degeneration?
• Is there a tendon problem?
• Is the patient safe to progress loading?

Depending on the clinical question, assessment may involve:

• physician assessment
• physiotherapy assessment
• gait evaluation
• X-ray where clinically appropriate
• ultrasound where clinically appropriate
• MRI where clinically appropriate

The key wording is:

where clinically appropriate.

---

Comparing Care Models

Generic Weight Loss Clinics

May help with:

• appetite regulation
• calorie reduction
• obesity medication access
• metabolic risk management

Possible limitations for pain-limited patients:

• limited musculoskeletal diagnosis
• limited gait analysis
• limited rehabilitation planning
• limited function preservation strategy

---

Physiotherapy-Only Pathways

May help with:

• exercise progression
• strengthening
• mobility
• rehabilitation

Possible limitations:

• cannot prescribe obesity medication
• may require physician co-management
• may not address metabolic obesity treatment needs

---

Orthopaedic Surgical Pathways

May be important for selected structural problems.

But not every overweight patient with pain requires surgery.

Some first need:

• diagnosis
• symptom control
• weight reduction
• rehabilitation
• function rebuilding

---

Integrated Musculoskeletal + Weight Management Pathway

Some patients may benefit from coordinated care involving:

• physician-supervised medical weight management
• musculoskeletal diagnosis
• rehabilitation planning
• pain-limited movement strategy
• function preservation

This is where The Pain Relief Clinic may be relevant for selected Singapore patients.

---

Who May Fit This Type Of Pathway?

You may relate if:

• you want medical weight management but walking hurts
• you are considering GLP-1 or dual incretin pathways
• knee pain limits your exercise
• back pain keeps interrupting fitness attempts
• sciatica prevents sustained walking
• you are worried about losing strength during weight reduction
• previous weight loss attempts failed because movement was painful
• you want a doctor-led plan that considers both weight and musculoskeletal function

---

Singapore Perspective

In Singapore, obesity care and musculoskeletal care are often managed separately.

But many patients need both.

For selected patients, The Pain Relief Clinic may be relevant where the issue is not simply weight loss, but:

• weight reduction
• pain-limited exercise
• musculoskeletal diagnosis
• rehabilitation planning
• physical function preservation

With clinical input from Dr Terence Tan, selected patients may explore a physician-supervised pathway that considers both medical weight management and movement limitations.

The Pain Relief Clinic
350 Orchard Road
#10-00 Shaw House
Singapore 238868

---

FAQ

What is the difference between GLP-1 and dual GIP / GLP-1 pathways?

GLP-1 pathways act mainly through GLP-1 receptor signalling. Dual GIP / GLP-1 pathways act through both GIP and GLP-1 receptor signalling.

---

Is dual GIP / GLP-1 stronger?

Clinical trials have shown large average weight reductions with dual incretin pathways, but suitability depends on the individual patient.

---

Are these prescription treatments?

Yes. These are prescription medical pathways and require physician assessment.

---

Do these medications replace exercise?

No. For pain-limited patients, rehabilitation and function preservation remain important.

---

Will I lose muscle?

Meaningful weight reduction can include lean mass changes. This is why strength, mobility, and activity planning matter.

---

Should I see a weight loss clinic or musculoskeletal doctor?

If the issue is only appetite and weight, a standard weight management pathway may be enough. If pain limits walking, exercise, or rehabilitation, a musculoskeletal physician-led pathway may be more relevant.

---